{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:20:05Z","timestamp":1792516805743,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Venetoclax was first approved for continuous use in relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL), but the efficacy and consequences of very long-term BCL2 inhibition are unknown. We describe the frequency, characteristics, and outcomes of patients with R\/R CLL treated with &amp;gt;5 years of continuous venetoclax. Long-term responders (&amp;gt;5 years of continuous therapy without progressive disease [PD]) were identified from a cohort of 86 patients with R\/R CLL treated with continuous venetoclax with or without rituximab. Landmark analyses at 2 and 5 years assessed association between undetectable measurable residual disease (uMRD; 10\u22124 peripheral blood flow cytometry) and progression-free survival (PFS). Next-generation sequencing was performed at PD for BCL2 and TP53 mutations. Twenty-nine patients (33%) were long-term responders. Compared to those with PD within 5 years, they were more likely to have mutated immunoglobulin heavy chain variable region (44% vs 14%; P = .029), noncomplex karyotype (89 vs 50%; P = .043), and uMRD (79 vs 30%; P&amp;lt; .001). At a median follow-up of 11.1 years, 76% had discontinued venetoclax, mostly due to PD. In a landmark analysis of patients continuing venetoclax beyond 2 years, 5-year PFS was 87% for those with uMRD vs 45% without (hazard ratio, 1.30; 95% confidence interval, 1.12-1.52; P = .001). BCL2 mutations were detected in 4 of 8 patients at PD. Grade \u22653 toxicities, including infection (51%), neutropenia (20%), and thrombocytopenia (10%), occurred at consistent frequency throughout treatment. Long-term responses to continuous venetoclax occur in approximately one-third of patients with R\/R CLL. Sustained uMRD confers the most favorable outcomes, although all patients show a continuous risk of relapse, infection, and cytopenias.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020789","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:01:08Z","timestamp":1784937668000},"page":"6459-6467","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-0120","authenticated-orcid":false,"given":"Sean","family":"McKeague","sequence":"first","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2Department of Haematology, Royal Brisbane and Women's Hospital, Herston, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-2432","authenticated-orcid":false,"given":"Thomas E.","family":"Lew","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lowe","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leishong","family":"Lau","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-6031","authenticated-orcid":false,"given":"Philip A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Whitechurch","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia"},{"name":"4School of Nursing and Midwifery, La Trobe University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3239-6065","authenticated-orcid":false,"given":"Dennis","family":"Carney","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Wolf","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Reynolds","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"5National Centre of Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia"},{"name":"6Department of Infectious Diseases and Immunology, Austin Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piers","family":"Blombery","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-6835","authenticated-orcid":false,"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"3Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"7Department of Medical Biology, The University of Melbourne, Parkville, Australia"},{"name":"8Walter and Eliza Hall Institute of Medical Research, Parkville, Australia"},{"name":"9Centre for Cancer Research, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3515-0215","authenticated-orcid":false,"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"7Department of Medical Biology, The University of Melbourne, Parkville, Australia"},{"name":"8Walter and Eliza Hall Institute of Medical Research, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"6","key":"2026101310434537100_bib1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3390\/jpm11060463","article-title":"Review of venetoclax in CLL, AML and multiple myeloma","volume":"11","author":"Lasica","year":"2021","journal-title":"J Pers Med"},{"issue":"4","key":"2026101310434537100_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"2026101310434537100_bib3","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026101310434537100_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2026101310434537100_bib5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood.2020009578","article-title":"Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy","volume":"138","author":"Ma","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2026101310434537100_bib6","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"2026101310434537100_bib7","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"8","key":"2026101310434537100_bib8","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"2026101310434537100_bib9","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJMoa2515458","article-title":"Fixed-duration versus continuous treatment for chronic lymphocytic leukemia","volume":"394","author":"Al-Sawaf","year":"2026","journal-title":"N Engl J Med"},{"issue":"19","key":"2026101310434537100_bib10","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"S2","key":"2026101310434537100_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/hon.3163_156","article-title":"MURANO: final 7 year follow up and retreatment analysis in venetoclax-rituximab (VenR)-treated patients with relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL)","volume":"41","author":"Kater","year":"2023","journal-title":"Hematol Oncol"},{"issue":"8","key":"2026101310434537100_bib12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"23","key":"2026101310434537100_bib13","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2024025525","article-title":"The MURANO study: final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL","volume":"145","author":"Kater","year":"2025","journal-title":"Blood"},{"issue":"25","key":"2026101310434537100_bib14","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.2020004782","article-title":"BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax","volume":"135","author":"Lin","year":"2020","journal-title":"Blood"},{"issue":"18","key":"2026101310434537100_bib15","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"23","key":"2026101310434537100_bib16","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"2026101310434537100_bib17","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.2025032160","article-title":"Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13\/GAIA trial","volume":"147","author":"F\u00fcrstenau","year":"2026","journal-title":"Blood"},{"issue":"8","key":"2026101310434537100_bib18","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/bloodadvances.2023011741","article-title":"Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia","volume":"8","author":"Stilgenbauer","year":"2024","journal-title":"Blood Adv"},{"issue":"15","key":"2026101310434537100_bib19","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv"},{"issue":"33","key":"2026101310434537100_bib20","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.2217\/fon-2022-0456","article-title":"MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"18","author":"Ryan","year":"2022","journal-title":"Future Oncol"},{"issue":"5","key":"2026101310434537100_bib21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol"},{"issue":"13","key":"2026101310434537100_bib22","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2026101310434537100_bib23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2026101310434537100_bib24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026101310434537100_bib25","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/10428194.2021.1986217","article-title":"Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial","volume":"63","author":"Cochrane","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"2026101310434537100_bib26","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2026101310434537100_bib27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/jha2.177","article-title":"Addition of rituximab in relapsed\/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy","volume":"2","author":"Handunnetti","year":"2021","journal-title":"EJHaem"},{"issue":"34","key":"2026101310434537100_bib28","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026101310434537100_bib29","doi-asserted-by":"crossref","first-page":"100824","DOI":"10.1016\/j.blre.2021.100824","article-title":"Revisiting Richter transformation in the era of novel CLL agents","volume":"49","author":"Petrackova","year":"2021","journal-title":"Blood Rev"},{"issue":"25","key":"2026101310434537100_bib30","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2026101310434537100_bib31","doi-asserted-by":"crossref","first-page":"E47","DOI":"10.1002\/ajh.26411","article-title":"Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy","volume":"97","author":"Popovic","year":"2022","journal-title":"Am J Hematol"},{"issue":"9","key":"2026101310434537100_bib32","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"18","key":"2026101310434537100_bib33","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","article-title":"Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"24","author":"Davids","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2026101310434537100_bib34","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/s41375-019-0481-1","article-title":"Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies","volume":"33","author":"Rogers","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"2026101310434537100_bib35","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1002\/hem3.146","article-title":"Long-term immune changes in patients with relapsed\/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab","volume":"8","author":"Kater","year":"2024","journal-title":"Hemasphere"},{"issue":"12","key":"2026101310434537100_bib36","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1038\/s41375-020-0987-6","article-title":"Second cancer incidence in CLL patients receiving BTK inhibitors","volume":"34","author":"Bond","year":"2020","journal-title":"Leukemia"},{"issue":"18","key":"2026101310434537100_bib37","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1182\/bloodadvances.2023010236","article-title":"Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study","volume":"7","author":"Moreno","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"2026101310434537100_bib38","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2010.218","article-title":"Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy","volume":"24","author":"Carney","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"2026101310434537100_bib39","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.2021012775","article-title":"Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL","volume":"139","author":"Blombery","year":"2022","journal-title":"Blood"},{"issue":"S3","key":"2026101310434537100_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70093_OT02","article-title":"Ot02 | Cll18\/Moirai trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in treatment-naive Cll\/Sll","volume":"43","author":"Cramer","year":"2025","journal-title":"Hematol Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6459\/2590960\/blooda_adv-2026-020789-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6459\/2590960\/blooda_adv-2026-020789-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:43:55Z","timestamp":1791902635000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6459\/569870\/Long-term-outcomes-with-continuous-venetoclax-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":40,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020789","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,25]]}}}